The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study
18 Years
N/A
Both
Lung Cancer
Trial Information
The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study
OBJECTIVES:
- Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV
non-small cell lung cancer (NSCLC) and in healthy participants.
- Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron
emission tomography in patients with stage III or IV NSCLC.
OUTLINE: This is a pilot study.
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body
dynamic scans comprising positron emission tomography.
Blood is collected during and after imaging to measure radioactivity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Inclusion Criteria:
- Must meet 1 of the following criteria:
- Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
- Stage III or IV disease
- Clinically assessed with
- Healthy participant
Exclusion Criteria:
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Biodistribution of fluorine F 18 FEQA
Safety Issue:
No
Principal Investigator
Johannes Czernin, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Jonsson Comprehensive Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
CDR0000529363
NCT ID:
NCT00444223
Start Date:
May 2004
Completion Date:
Related Keywords:
- Lung Cancer
- stage IIIA non-small cell lung cancer
- stage IIIB non-small cell lung cancer
- stage IV non-small cell lung cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Jonsson Comprehensive Cancer Center at UCLA | Los Angeles, California 90095-1781 |
